Sign In
Buy WXXWY
$9.88
+0.180 (+1.86%)
At Close: Jul 31, 2026
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation sta
Focus: China pharma projects disrupted by Sino-US tensions
07:10pm, Tuesday, 17'th Jun 2025
Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of th
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
06:10am, Monday, 09'th Jun 2025
The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches annually with expansion potential to 60,000L. It
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injecti
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
06:47am, Tuesday, 29'th Apr 2025
Contributing to United Nations Sustainable Development Goals Enhancing transparency and effectiveness for corporate governance Empowering employees and delivering positive impact to communities Accele
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
04:30am, Tuesday, 22'nd Apr 2025
Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI , April 22, 20
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
02:30am, Friday, 18'th Apr 2025
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors- Proprietary process innovation reduces protei
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
09:07am, Monday, 14'th Apr 2025
SHANGHAI , April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
06:30am, Tuesday, 25'th Mar 2025
Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
08:30pm, Sunday, 23'rd Mar 2025
SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
08:30pm, Thursday, 20'th Mar 2025
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and s
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
07:30pm, Monday, 03'rd Mar 2025
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system.
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
11:30pm, Wednesday, 26'th Feb 2025
WUXI, China , Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
04:00am, Tuesday, 18'th Feb 2025
Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation fo
Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for
